Abstract:Background Colorectal carcinoma(CRC) is one of the most common malignant tumours, which main cause of death is tumour metastasis. The role of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) in cancer has not been well studied. This study reveals a new role of METTL3 in promoting CRC tumour progress through m6A modification of SOX2 (SRY-box 2) and influencing the Epithelial-Mesenchymal Transition process. Methods Western blot and Immunohistochemistry were used to detect METTL3 expression in cell lines and patient‘s tissues. The MTS assay, invasion assay, sphere formation assay was performed to detect the function of METTL3. Cell based xenograft model and PDX model revealed the clinical benefits of target METTL3 in vivo. Transcriptome sequencing and uencing were used to screen the m6A target genes, and MeRIP qPCR was used to detect the m6A level of the target gene. Results Using TCGA database, we found that METTL3 was significantly upregulated in human CRC and high expression of METTL3 in metastasis CRC was associated with poor prognosis of patients. Knockdown of METTL3 in CRC sample cell line and SW620 dramatically suppressed cellular proliferation, migration and sphere formation in vitro. METTL3 inhibition suppresses CRC tumorigenesis and metastasis in both cell models and PDX models in vivo. Mechanistically, we performed RNA-sequencing and MeRIP- sequencing in SW480 and SW620 CRC cell lines and SOX2 was identified as the target of METTL3-mediated m6A modification. The protein level, m6a modification level, and RNA stability of SOX2 was significantly decreased upon METTL3 inhibition. Comparing with the m6a-site-mutant SOX2, only the wildtype modified SOX2 promoting tumour progress through activating EMT process. The RNA and protein level of SOX2 downstream genes were dramatically diminished after METTL3 knockdown and both SOX2 and its target genes showed a positive correlation with METTL3 expression in CRC patients. Conclusions In summary, we demonstrated that METTL3, acting as an oncogene, was frequently upregulated in human CRC and contributed to CRC metastasis. METTL3 maintained SOX2 expression to activate EMT process through the m6A dependent mechanism. Thus, our findings reveal an important role of METTL3 and provide a potential target of treatment in colorectal carcinoma.

M6a Methyltransferase METTL3-mediated Lncrna FOXD2-AS1 Promotes the Tumorigenesis of Cervical Cancer

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

METTL3 Regulates the Malignancy of Cervical Cancer Via Post-Transcriptional Regulation of RAB2B

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

C-Myc/mettl3/linc01006 /LINC01006 Positive Feedback Loop Promotes Migration, Invasion and Proliferation of Non-Small Cell Lung Cancer

RNA N6-methyladenosine Modification Mediates Downregulation of NR4A1 to Facilitate Malignancy of Cervical Cancer.

METTL3's role in cervical cancer development through m6A modification

METTL3-induced DLGAP1-AS2 promotes non-small cell lung cancer tumorigenesis through m6A/c-Myc-dependent aerobic glycolysis

LncRNA RASAL2-AS1 promotes METTL14-mediated m6A methylation in the proliferation and progression of head and neck squamous cell carcinoma

METTL3 facilitates the progression of cervical cancer by m6A modification-mediated up-regulation of NEK2

METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA

LINC00426, a Novel M6a-Regulated Long Non-Coding RNA, Induces EMT in Cervical Cancer by Binding to ZEB1

Methyltransferase-like 3 Induces the Development of Cervical Cancer by Enhancing Insulin-Like Growth Factor 2 Mrna-Binding Proteins 3-Mediated Apoptotic Chromatin Condensation Inducer 1 Mrna Stability

N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification

IDDF2018-ABS-0233 N6-adenosine Methyltransferase METTL3 Promotes Tumour Metastasis Via SOX2 MRNA M6A Modification in Colorectal Carcinoma

LncRNA CALML3-AS1 Modulated by M6a Modification Induces BTNL9 Methylation to Drive Non-Small-cell Lung Cancer Progression.

N6-methyladenosine-induced METTL1 promotes tumor proliferation via CDK4

METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2

N<SUP>6</SUP>-Methyladenosine Associated Silencing of miR-193b Promotes Cervical Cancer Aggressiveness by Targeting CCND1

The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma

METTL3 Regulates the Translation of Oncogene Myc through m6A Modification and Promotes the Occurrence and Development of Cervical Cancer